Truist Financial analyst Joon Lee maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report) today. The company’s shares closed ...

Teva and Sanofi's duvakitug showed promising results in a Phase 2b study for ulcerative colitis and Crohn's disease, with ...

Research analysts at HC Wainwright cut their Q1 2025 earnings estimates for Axsome Therapeutics in a research report issued ...

We recently published a list of the 10 Best Performing Pharma Stocks So Far in 2025. In this article, we are going to take a ...

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its target price increased by equities research analysts at HC ...

Analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of Axsome Therapeutics in a research note issued to investors on Thursday, February 20th. HC Wainwright analyst R ...

Leerink Partnrs lowered their FY2028 earnings per share estimates for Axsome Therapeutics in a research note issued on ...

Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Free Report) shares hit a new 52-week high during trading on Friday after HC Wainwright raised their price target on the stock from $190.00 to $200.00. HC ...

William Blair cut their Q1 2025 earnings per share estimates for Axsome Therapeutics in a report issued on Tuesday, February ...

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its price objective lifted by equities research analysts at Needham & Company LLC from $133.00 to $153.00 in a report released on ...

Axsome's stock has risen 47% since my August recommendation, driven by FDA approvals and revenue growth. See why I maintain ...

Cantor Fitzgerald reaffirmed their overweight rating on shares of Axsome Therapeutics (NASDAQ:AXSM – Free Report) in a research report sent to investors on Wednesday morning,Benzinga reports. They ...